Merck KGaA Acquires SpringWorks Therapeutics for $3.4B

Merck Acquires Caraway Therapeutics

November 21, 2023

Biotechnology

Merck (MSD) will acquire Caraway Therapeutics, a Cambridge, Massachusetts–based preclinical biopharmaceutical company, for up to $610 million in potential consideration, including an undisclosed upfront payment and contingent milestone payments. The acquisition is intended to strengthen Merck’s research pipeline and capabilities in developing small-molecule treatments for genetically defined neurodegenerative and rare diseases.

Kyowa Kirin Acquires Orchard Therapeutics

October 5, 2023

Biotechnology

Kyowa Kirin Co., Ltd. agreed to acquire Orchard Therapeutics plc for $16.00 per ADS in cash plus a $1.00 contingent value right (CVR), representing a potential total equity value of approximately $477.6 million. The acquisition gives Kyowa Kirin a leading HSC gene therapy platform and commercial asset Libmeldy, accelerating development and commercialization of Orchard's rare-disease gene therapies.

Scaleworks Acquires SearchSpring

February 4, 2021

Cloud & SaaS

Scaleworks, a San Antonio-based venture equity firm, has acquired SearchSpring, an 11-year-old provider of AI/ML-powered e-commerce site search and merchandising solutions. SearchSpring founder and CEO Gareth Dismore will depart and Scaleworks has named retail-technology veteran Peter Messana as CEO to accelerate product and go-to-market expansion for SMB and direct-to-consumer retailers.

Merck to Acquire Harpoon Therapeutics for $680M

January 8, 2024

Biotechnology

Merck has agreed to acquire clinical-stage immunotherapy company Harpoon Therapeutics for $23.00 per share in cash, representing an approximate total equity value of $680 million. The acquisition gives Merck access to Harpoon's TriTAC / ProTriTAC platforms and lead candidate HPN328 (a DLL3-targeting T‑cell engager) to enhance its oncology pipeline; the deal is expected to close in the first half of 2024, subject to customary conditions.

Merck Acquires OncoImmune

November 23, 2020

Biotechnology

Merck will acquire all outstanding shares of clinical-stage biopharmaceutical OncoImmune for $425 million upfront in cash, with additional sales-based and regulatory milestone payments possible. The deal centers on accelerating development of OncoImmune’s CD24Fc for severe and critical COVID-19; non-CD24Fc assets will be spun out into a new company in which Merck will invest $50 million for a minority stake.

Merck to Acquire Imago BioSciences, Inc.

November 21, 2022

Pharmaceuticals

Merck has agreed to acquire clinical-stage biopharmaceutical company Imago BioSciences for $36.00 per share, representing an approximate equity value of $1.35 billion. The acquisition adds Imago's lead LSD1 inhibitor bomedemstat to Merck's hematology pipeline and is expected to close after a tender offer and customary regulatory clearances in early 2023.